Duke University
Low household income may predict higher risk for 30-day HF readmission
CHICAGO — Adults with an index HF hospitalization were 20% more likely to be readmitted within 30 days for a HF-specific cause if they lived in a low-income area as opposed to a high-income one, researchers reported.
Botulinum toxin injection does not prevent postoperative AF: NOVA
CHICAGO — Epicardial botulinum toxin type A injected into epicardial fat pads after cardiac surgery did not suppress incidence of postoperative atrial fibrillation compared with placebo, according to findings from the NOVA study.
In-hospital peer-to-peer consult may improve guideline-directed therapy in HFrEF
CHICAGO — A clinician level peer-to-peer consultation may increase use of and optimize guideline-directed medical therapy in patients with HFrEF hospitalized for any cause compared with usual care, a speaker reported.
Black women less likely to receive guideline-concordant therapy for ovarian cancer
Black women in the U.S. appeared less likely than white women to receive guideline-concordant treatment for ovarian cancer, according to a study published in Journal of the National Comprehensive Cancer Network.
Revaccination guidance after cell therapy established for some, ‘evolving’ for others
Guidelines on revaccination after cell therapy are clear for some patients but lack evidence-based consensus for others, according to an expert in infectious disease who spoke at NCCN 2022 Annual Congress: Hematologic Malignancies.
Precision testing strategy strongly benefits stable patients with suspected CAD
CHICAGO — In stable symptomatic patients with suspected CAD, a precision testing strategy was linked to a 70% reduction in death, MI or catheterization without obstructive CAD at 1 year compared with the usual testing, researchers reported.
Methylprednisolone does not reduce odds of poor outcomes in infant heart surgery
CHICAGO — In infants undergoing heart surgery with cardiopulmonary bypass, the use of the steroid methylprednisolone did not reduce odds of a worse outcome compared with placebo, according to the STRESS trial.
Loop diuretic choice does not reduce all-cause death in HF: TRANSFORM-HF
CHICAGO — A treatment strategy of torsemide vs. furosemide did not improve long-term clinical outcomes for adults hospitalized with HF, including all-cause mortality and all-cause hospitalization, researchers reported.
Overcoming physician ‘discomfort’: What rheumatologists need to know about birth control
Following the Supreme Court’s decision in June overturning Roe v. Wade, communication regarding effective and safe birth control in certain patients, including those with lupus and other rheumatic disease, has become immensely important.
Q&A: Trial to assess phage therapy in patients with cystic fibrosis
A trial to assess bacteriophage, or “phage,” therapy, which utilizes a virus to target specific bacteria and leave behind other bacteria and human cells, is underway among patients with cystic fibrosis, according to an NIH press release.